Royce & Associates LP Decreases Stake in Insmed Incorporated (NASDAQ:INSM)

Royce & Associates LP lessened its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 5.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 90,027 shares of the biopharmaceutical company’s stock after selling 5,000 shares during the period. Royce & Associates LP’s holdings in Insmed were worth $6,215,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Atria Investments Inc lifted its stake in shares of Insmed by 61.7% during the third quarter. Atria Investments Inc now owns 4,985 shares of the biopharmaceutical company’s stock worth $364,000 after buying an additional 1,902 shares during the period. GSA Capital Partners LLP purchased a new position in Insmed in the 3rd quarter worth $376,000. Oppenheimer Asset Management Inc. lifted its position in Insmed by 115.7% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 14,449 shares of the biopharmaceutical company’s stock worth $1,055,000 after acquiring an additional 7,751 shares during the period. KBC Group NV grew its stake in Insmed by 20.4% during the 3rd quarter. KBC Group NV now owns 4,310 shares of the biopharmaceutical company’s stock valued at $315,000 after purchasing an additional 730 shares during the last quarter. Finally, OneDigital Investment Advisors LLC acquired a new position in shares of Insmed in the third quarter valued at about $232,000.

Insider Buying and Selling

In other news, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50. Following the transaction, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at approximately $26,912,553.60. This trade represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the transaction, the insider now owns 97,083 shares in the company, valued at $7,766,640. The trade was a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 550,957 shares of company stock worth $42,859,028. Insiders own 4.60% of the company’s stock.

Insmed Trading Down 1.0 %

Shares of INSM stock opened at $76.99 on Wednesday. The stock has a 50 day simple moving average of $76.61 and a 200-day simple moving average of $73.70. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The company has a market cap of $13.94 billion, a price-to-earnings ratio of -13.77 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. On average, equities research analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

INSM has been the subject of a number of research reports. Guggenheim reaffirmed a “buy” rating and set a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. Wells Fargo & Company lifted their price objective on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. Royal Bank of Canada initiated coverage on shares of Insmed in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $100.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Finally, Morgan Stanley increased their price target on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $93.33.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.